Biochips to test toxicity of new drugs outside animal body
Posted by evolvingwheel on December 29, 2007
So a big pharma creates a drug molecule with the potential of becoming a blockbuster. $4 billion dollars have been spent in R&D and the drug-discovery life-cycle . The drug is now up for clinical trials and gets canned because of toxicity reported in animal and human treatments. The company tries to dilute the risk by spreading the failed investment into other drug development and profit margins. Future blockbuster drugs costs astronomically high!
Now consider that a new method of testing has been found that tests the toxicity of a drug-in-process way early in the discovery cycle. Guess how much investment can be saved by deflecting the risk of a flop show towards the end of the process. Researchers at Rensselaer Polytechnic Institute in Troy, N.Y., the University of California, Berkeley, and Solidus Biosciences, Inc. have developed a biochip technology that claims to reveal the potential toxicity of chemicals and drug candidates during early experiments. Read the article [here].
As in earlier cases, I am not going to talk about the technology behind it. You can read that in the article itself. I will rather try to analyze briefly the ecosystem dynamic around this innovation and what could be the potential lines of developments/creations in the industry.
- First thing, if this practice catches up, how will the clinical testing industry adjust with the new toxicity test way early in the cycle? How will those business components rehabilitate?
- We test drugs on animals earlier for toxicity and use that as a predicate for reactions on humans. Now that is often challenged. However, will the new chips really curtail the testing on animals? EU has already banned several testing on animals considering them inhumane. This policy enactment will definitely drive business development around these chips and their commercialization. How will the market get saturated with this technology and how long will that take. Will thestart-up be able to survive as bigger giants get into the game? If this technology is patented (which it is), what other methods can other companies utilize to enter this market? If there is no other than this then the market barrier is quite high. In that case there could be licensing in the horizon!
- Custom drugs?? – “Ultimately, each person would have their own DataChip or MetaChip that contains their own genetic information,” Dordick says, noting that most drugs on the market today are “one size fits all.” —- Now that could be something over the coming years. If we have our genetic makeup embedded in such chips and drug companies start developing molecules customized to our code, will that change the dynamics of drug development significantly. Is custom drug through custom tests the next generation of development ahead? That’s where I will be interested. And guess what – one field that will be greatly leveraged is clinical informatics and bio- informatics.
Similar article of Interest: